Beardsley D S, Spiegel J E, Jacobs M M, Handin R I, Lux S E
J Clin Invest. 1984 Nov;74(5):1701-7. doi: 10.1172/JCI111587.
The precise pathogenic mechanism of platelet destruction in immune thrombocytopenias is not known, although many investigators have found that platelet-associated IgG is increased in these diseases. We report here the differentiation between specific binding of anti-platelet antibody, associated with platelet destruction, and the ubiquitous presence of nonspecific, platelet-associated IgG. Using an electrophoretic separation and antibody overlay technique, we have identified a specific membrane protein that bears target platelet antigens in immune thrombocytopenias. When posttransfusion purpura serum was studied, antibody binding to the PlA1 antigen on glycoprotein IIIa was readily distinguished from the nonspecific binding of immunoglobulin to a protein of 200,000 mol wt. After reduction of disulfide bonds, the PlA1 antigenicity was not observed, and IgG bound nonspecifically to a protein band with an apparent molecular weight of 45,000. We have also identified anti-platelet antibodies in patients with idiopathic thrombocytopenic purpura and determined their antigenic specificity. Antibodies which bind to a 100,000-mol wt protein were found in nine of thirteen patients with chronic disease. The antigens in three of these cases were studied in detail by using both reduced and nonreduced control and Glanzmann's thrombasthenic platelets. Target antigens were localized to glycoprotein IIIa, but are different from PlA1. The immune thrombocytopenic purpura antigenic system is clearly distinguished from nonspecific platelet-associated IgG. Sera from eight children with acute idiopathic thrombocytopenic purpura were also studied. In all cases, the nonspecific IgG binding to the 200,000-mol wt protein was observed. However, we were unable to demonstrate antibody binding to glycoprotein IIIa, which suggested that the acute childhood form of this disease may have a different pathogenic mechanism than that of the autoimmune chronic cases.
尽管许多研究人员发现免疫性血小板减少症中血小板相关IgG升高,但这些疾病中血小板破坏的确切致病机制尚不清楚。我们在此报告与血小板破坏相关的抗血小板抗体的特异性结合与非特异性、血小板相关IgG普遍存在之间的区别。使用电泳分离和抗体覆盖技术,我们在免疫性血小板减少症中鉴定出一种携带靶血小板抗原的特异性膜蛋白。研究输血后紫癜血清时,抗体与糖蛋白IIIa上的PlA1抗原的结合很容易与免疫球蛋白与200,000摩尔质量蛋白的非特异性结合区分开来。二硫键还原后,未观察到PlA1抗原性,IgG非特异性结合到一条表观分子量为45,000的蛋白带上。我们还在特发性血小板减少性紫癜患者中鉴定出抗血小板抗体并确定了其抗原特异性。在13例慢性病患者中的9例中发现了与100,000摩尔质量蛋白结合的抗体。其中3例的抗原通过使用还原和非还原对照以及Glanzmann血小板无力症血小板进行了详细研究。靶抗原定位于糖蛋白IIIa,但与PlA1不同。免疫性血小板减少性紫癜抗原系统与非特异性血小板相关IgG明显不同。还研究了8名急性特发性血小板减少性紫癜儿童的血清。在所有病例中,均观察到非特异性IgG与200,000摩尔质量蛋白的结合。然而,我们无法证明抗体与糖蛋白IIIa的结合,这表明这种疾病的儿童急性形式可能具有与自身免疫性慢性病例不同的致病机制。